We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
Turnover
32.84%
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
-20.31%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$268M
AUM Growth
-$125M
(-32%)
Cap. Flow
-$27.2M
Cap. Flow
% of AUM
-10.13%
Top 10 Holdings %
Top 10 Hldgs %
57.14%
Holding
61
New
14
Increased
11
Reduced
11
Closed
14
Avg Time Held
1
year
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Avalo Therapeutics
AVTX
|
+$8.46M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
+$7.06M |
| 3 |
Immunogen Inc
IMGN
|
+$6.2M |
| 4 |
Abeona Therapeutics
ABEO
|
+$3.93M |
| 5 |
AIMT
Aimmune Therapeutics
AIMT
|
+$3.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$10M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$8.4M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$7.01M |
| 4 |
Amarin Corp
AMRN
|
+$6.38M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$6.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Iovance Biotherapeutics
IOVA
$6.17B
| – | – |
-325,000
| Closed | -$3.66M | – |
|
52
Ocular Therapeutix
OCUL
$1.51B
| – | – |
-800,000
| Closed | -$5.5M | – |
|
|
53
Ultragenyx Pharmaceutical
RARE
$1.43B
| – | – |
-80,000
| Closed | -$6.11M | – |
|
|
54
Xenon Pharmaceuticals
XENE
$3.24B
| – | – |
-465,200
| Closed | -$7.01M | – |
|
55
Tvardi Therapeutics
TVRD
$13.5M
| – | – |
-3,611
| Closed | -$3.11M | – |
|
|
INFI
56
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| – | – |
-275,000
| Closed | -$745K | – |
|
|
BFRA
57
DELISTED
Biofrontera AG American Depositary Shares
BFRA
| – | – |
-79,007
| Closed | -$1.07M | – |
|
|
AMAG
58
DELISTED
AMAG Pharmaceuticals
AMAG
| – | – |
-420,000
| Closed | -$8.4M | – |
|
|
FOMX
59
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| – | – |
-91,000
| Closed | -$521K | – |
|
|
ACHN
60
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-275,000
| Closed | -$1.01M | – |
|
|
CORI
61
DELISTED
Corium International, Inc.
CORI
| – | – |
-550,000
| Closed | -$5.23M | – |
|
Similar funds
CFO
PFM
HBCM
AI
TPA
ZDA
NW
TFA
Opaleye Management's Q4 2018 Portfolio in Review
As of Q4 2018, Opaleye Management held 61 positions worth $268M, down 32% from $393M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Opaleye Management withdrew a net $27.2M in Q4 2018, closing 14 positions and reducing 11 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $10M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Opaleye Management opened a new position in Avalo Therapeutics worth $6.21M.
- Opaleye Management's largest Q4 2018 buy was Avalo Therapeutics: 759 shares worth $6.21M.
- Opaleye Management added most to Epizyme, Inc in Q4 2018, an estimated $7.06M increase.
- Opaleye Management's biggest Q4 2018 reduction was Amarin Corp, cutting an estimated $6.38M.
- Opaleye Management fully exited Agios Pharmaceuticals in Q4 2018, selling an estimated $10M.
- Opaleye Management's ten largest holdings make up 57% of its $268M portfolio in Q4 2018.
- Opaleye Management opened 14 new positions and closed 14 in Q4 2018.
- Opaleye Management's portfolio value fell 32% quarter-over-quarter to $268M.
Based on Opaleye Management's 13F filing for Q4 2018, filed 14 Feb 2019.